Evidence map›Paper›PMID 42823733›Full record

ArticleJournal of hematology & oncology2026

Mitochondrial genetic variation as a novel predictor of graft-versus-host disease after stem-cell transplantation in myelodysplastic neoplasms.

Shahram Arsang-Jang, Tao Zhang, Maryam Rafati, Yung-Tsi Bolon, Stephen R Spellman, Zhongyuan Chen, Kristine Jones, Jia Liu, Najla El Jurdi, Xiaowu Gai and 5 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shahram Arsang-JangDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, HRC 5860, USA.
Tao ZhangCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, USA.
Maryam RafatiDivision of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, Rockville, MD, USA.
Yung-Tsi BolonCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, USA.
Stephen R SpellmanCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, USA.
Zhongyuan ChenDivision of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
Kristine JonesDivision of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, Rockville, MD, USA.
Jia LiuDivision of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, Rockville, MD, USA.
Najla El JurdiImmune Deficiency Cellular Therapy Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Xiaowu GaiLinda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Raul UrrutiaLinda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Shahinaz M GadallaDivision of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, Rockville, MD, USA.
Paul L AuerDivision of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
Wael SaberDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, HRC 5860, USA.
Jing DongDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, HRC 5860, USA. jidong@mcw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft-versus-host disease (GvHD) remains a major cause of morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation. Building on prior evidence implicating mitochondrial DNA (mtDNA) variation in myelodysplastic neoplasms (MDS), we investigated the prognostic impact of recipient and donor mtDNA variation on acute and chronic GvHD. Whole‑genome sequencing was performed on pretransplant samples from 494 MDS donor-recipient pairs (discovery cohort) from the Center for International Blood and Marrow Transplant Research (CIBMTR). Associations between mtDNA variations and acute GvHD grades II-IV (aGvHD24), grades III-IV (aGvHD34), and chronic GvHD (cGvHD) were assessed using cause-specific Cox proportional hazards models. Model discrimination was quantified using area under the curve (AUC). Findings were evaluated in an independent cohort of 295 MDS using targeted mtDNA deep sequencing. Among the recipient mtDNA gene associations identified in the discovery cohort, MT-ND2 for aGvHD34 (p = 1.1 × 10

Indexed as

DNA, MitochondrialGenetic VariationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAdultAgedFemaleHumansMaleMiddle AgedPrognosisDNA, Mitochondrial

Identifiers

PMID42823733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.